Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

By Tsuji Brian T  

Journal of Chemotherapy, Vol. 25, Iss. 1, 2013-02 ,pp. : 32-35

Maney Publishing

Access to resources Recommend Favorite

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

By Kaplan Nachum  

Journal of Chemotherapy, Vol. 25, Iss. 1, 2013-02 ,pp. : 18-25

Maney Publishing

Access to resources Recommend Favorite

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer

By            

International Journal of Oncology, Vol. 41, Iss. 1, 2012-01 ,pp. : 337-344

Spandidos Publications

Access to resources Recommend Favorite

Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma

By Storm Phillip   Renard Violette   Moriarity John   Tyler Betty   Wilentz Robb   Brem Henry   Weingart Jon  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 361-367

Springer Publishing Company

Access to resources Recommend Favorite